Trial · NCT07432516
Registered outcomes39
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 39
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Major or Clinically-Relevant Non-Major Bleeding (OPACT-P) | Within 1 year after enrollment | Bleeding Academic Research Consortium (BARC) type 2, 3, or 5 bleeding |
| Primary | Major Adverse Cardiac Events (OPACT-L) | Within 3 years after enrollment | A composite of all-cause death, spontaneous MI, stroke, coronary or peripheral revascularization, and hospitalization for cardiovascular events |
| Secondary | Key Secondray Outcomes for the OPACT-P trial | Withtin 1 and 3 years after enrollement | AA. MACCE (composite of all-cause death, spontaneous MI, stent thrombosis, stroke, or target-vessel revascularization) B. NACE: Major or clinically relevant non-major bleeding (BARC type 2, 3, 5) and MACCE C. BARC type 2 bleeding D. BARC type 3 bleeding E. BARC type 5 bleeding |
| Secondary | All-cause death (OPACT-P trial) | Withtin 1 and 3 years after enrollement | Number of participants who experienced all-cause death during the study period |
| Secondary | Cardiovascular death (OPACT-P trial) | Withtin 1 and 3 years after enrollement | Number of participants who experienced cardiovascular death during the study period |
| Secondary | Spontaneous MI (OPACT-P trial) | Withtin 1 and 3 years after enrollement | Number of participants who experienced spontaneous myocardial infarction during the study period |
| Secondary | Stroke (OPACT-P trial) | Withtin 3 years after enrollement | Number of participants who experienced stroke during the study period |
| Secondary | Target-vessel revascularization (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who underwent target-vessel revascularization during the study period |
| Secondary | Target-lesion revascularization (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who underwent target-lesion revascularization during the study period |
| Secondary | Definite or probable stent thrombosis (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who experienced definite or probable stent thrombosis during the study period |
| Secondary | Composite of all-cause death, spontaneous MI, or stroke (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who experienced the composite endpoint of all-cause death, spontaneous MI, or stroke |
| Secondary | Composite of cardiovascular death, spontaneous MI, or stent thrombosis (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who experienced the composite endpoint of cardiovascular death, spontaneous MI, or stent thrombosis |
| Secondary | Major or clinically relevant non-major bleeding - BARC type 2, 3, 5 (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who experienced major or clinically relevant non-major bleeding as defined by BARC type 2, 3, or 5 criteria |
| Secondary | Major or clinically relevant non-major bleeding - ISTH criteria (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who experienced major or clinically relevant non-major bleeding as defined by ISTH criteria |
| Secondary | Major or minor bleeding - TIMI criteria (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who experienced major or minor bleeding as defined by TIMI criteria |
| Secondary | Moderate, severe, or life-threatening bleeding - GUSTO criteria (OPACT-P trial) | Within 1 and 3 years after enrollment | Number of participants who experienced moderate, severe, or life-threatening bleeding as defined by GUSTO criteria |
| Secondary | Other prespecified analyses for the OPACT-P trial | Withtin 1 and 3 years after enrollement | A. Type of prescribed antiplatelet therapy B. Rate and reasons for non-adherence to the allocated treatment during study period |
| Secondary | All-cause death (OPACT-L trial) | Within 1 and 3 years after enrollment | Number of participants who experienced all-cause death during the study period |
| Secondary | Spontaneous MI (OPACT-L trial) | Within 1 and 3 years after enrollment | Number of participants who experienced spontaneous myocardial infarction during the study period |
| Secondary | Stroke (OPACT-L trial) | Within 1 and 3 years after enrollment | Number of participants who experienced stroke during the study period |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07432516/registered